A patient on Bilonatumomab for refractory B cell All is now resistance to the drug. Which drug to be used:-
Drug Mechanism Use Vorinostat HDAC inhibitor Cutaneous T cell lymphoma Brentuximab Man against CD30 Hodgkin lymphoma Pembrolizumab PD-1 Melanoma Lung Cancer Head and neck cancer Tisagenlecleucel Ca therapy ALL Blinatumomab Bispecific t-cell engages ( targets CD19 and CD3) ALL
Vorinostat
Brentuximab
Pembrolizumab
Tisagenlecleucel
JIPMER 2019